IONS

SEC source: 0000874015-20-000029 · edgar.xml · derivative · entry 8

CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,160

Underlying: Common Stock · 39,643 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-20-000029 · edgar.xml · derivative · entry 7

CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 5,545

Underlying: Common Stock · 5,545 shares

Expires not disclosed

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6 · derivative.exercise_price: Grant to reporting person's wife of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-20-000029 · edgar.xml · derivative · entry 6

CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,982

Underlying: Common Stock · 62,982 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-20-000029 · edgar.xml · nonDerivative · entry 4

CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 7,581

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-20-000029 · edgar.xml · nonDerivative · entry 3

CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 8,849

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-20-000029 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,935

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-20-000029 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-20-000024 · edgar.xml · derivative · entry 4

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,549

Underlying: Common Stock · 11,711 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as determined by Ionis.

SEC source: 0000874015-20-000024 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,612

Underlying: Common Stock · 21,612 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as determined by Ionis.

SEC source: 0000874015-20-000024 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,195

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-20-000024 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-20-000022 · edgar.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2027-01-08

F1 · derivative.exercise_date: Grant on 01/09/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/09/2020. 25% of the shares subject to the option will vest and become exercisable on 01/09/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-20-000018 · edgar.xml · derivative · entry 1

Swayze Eric · CIK 0001791058 · SVP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,528

Underlying: Common Stock · 27,528 shares

Expires 2027-01-01

F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-20-000012 · edgar.xml · derivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,299

Underlying: Common Stock · 60,299 shares

Expires 2027-01-01

F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-20-000014 · edgar.xml · derivative · entry 2

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,659

Underlying: Common Stock · 158,659 shares

Expires 2027-01-01

F2 · derivative.exercise_date: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-20-000014 · edgar.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,285

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019.

F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019.

SEC source: 0000874015-20-000016 · edgar.xml · derivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,461

Underlying: Common Stock · 54,461 shares

Expires 2027-01-01

F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-20-000010 · edgar.xml · derivative · entry 1

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,461

Underlying: Common Stock · 54,461 shares

Expires 2027-01-01

F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-20-000006 · edgar.xml · derivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,626

Underlying: Common Stock · 48,626 shares

Expires 2027-01-01

F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-20-000008 · edgar.xml · derivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 12,477

Underlying: Common Stock · 12,477 shares

Expires 2027-01-01

F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person or reporting person's wife (as indicated) of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-20-000008 · edgar.xml · derivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,709

Underlying: Common Stock · 141,709 shares

Expires 2027-01-01

F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person or reporting person's wife (as indicated) of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-20-000043 · edgar.xml · derivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,454

Underlying: Common Stock · 148,454 shares

Expires 2027-01-01

F2 · shares: The original Form 4 filed on January 6, 2020 reported a grant of 158,659 stock options to the reporting person which has been revised by this amendment to reflect the amount of the actual award granted to Dr. Monia.

F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-19-000156 · edgar.xml · derivative · entry 4

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,000 shares

Expires 2024-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

SEC source: 0000874015-19-000156 · edgar.xml · nonDerivative · entry 2

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,683

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.30 to $62.345, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-19-000156 · edgar.xml · nonDerivative · entry 1

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

SEC source: 0000874015-19-000154 · edgar.xml · derivative · entry 6

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,438 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant.

SEC source: 0000874015-19-000154 · edgar.xml · derivative · entry 5

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,196 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant.

SEC source: 0000874015-19-000154 · edgar.xml · nonDerivative · entry 4

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,460

F2 · kind: Shares sold to cover the option cost and tax withholding obligations pursuant to the Agreement.

F2 · shares: Shares sold to cover the option cost and tax withholding obligations pursuant to the Agreement.

SEC source: 0000874015-19-000154 · edgar.xml · nonDerivative · entry 3

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,474

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option in accordance with the Amendment to Outstanding Options Agreement dated November 9, 2015 between the reporting person and issuer ("Agreement"). The purchase and partial sale reported on this Form 4 was effective pursuant to the Agreement.

F1 · shares: Acquired as a result of exercising a stock option in accordance with the Amendment to Outstanding Options Agreement dated November 9, 2015 between the reporting person and issuer ("Agreement"). The purchase and partial sale reported on this Form 4 was effective pursuant to the Agreement.

SEC source: 0000874015-19-000154 · edgar.xml · nonDerivative · entry 2

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,036

F2 · kind: Shares sold to cover the option cost and tax withholding obligations pursuant to the Agreement.

F2 · shares: Shares sold to cover the option cost and tax withholding obligations pursuant to the Agreement.

SEC source: 0000874015-19-000154 · edgar.xml · nonDerivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,251

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option in accordance with the Amendment to Outstanding Options Agreement dated November 9, 2015 between the reporting person and issuer ("Agreement"). The purchase and partial sale reported on this Form 4 was effective pursuant to the Agreement.

F1 · shares: Acquired as a result of exercising a stock option in accordance with the Amendment to Outstanding Options Agreement dated November 9, 2015 between the reporting person and issuer ("Agreement"). The purchase and partial sale reported on this Form 4 was effective pursuant to the Agreement.

SEC source: 0000874015-19-000152 · edgar.xml · derivative · entry 4

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Underlying: Common Stock · 1,000 shares

Expires 2024-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant.

SEC source: 0000874015-19-000152 · edgar.xml · nonDerivative · entry 2

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,683

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.78 to $66.135, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-19-000152 · edgar.xml · nonDerivative · entry 1

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

SEC source: 0000874015-19-000150 · edgar.xml · derivative · entry 4

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 1,000 shares

Expires 2024-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant.

SEC source: 0000874015-19-000150 · edgar.xml · nonDerivative · entry 2

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,683

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.44 to $64.90, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-19-000150 · edgar.xml · nonDerivative · entry 1

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

SEC source: 0000874015-20-000004 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Indirect · By trust

Disclosed balance after: 700,391

F1 · kind: Represents a bona fide gift to a charitable organization.

SEC source: 0000874015-19-000148 · edgar.xml · derivative · entry 6

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,438

Underlying: Common Stock · 4,062 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant.

SEC source: 0000874015-19-000148 · edgar.xml · derivative · entry 5

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,196

Underlying: Common Stock · 504 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant.

SEC source: 0000874015-19-000148 · edgar.xml · nonDerivative · entry 4

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,055

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

SEC source: 0000874015-19-000148 · edgar.xml · nonDerivative · entry 3

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,117

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

SEC source: 0000874015-19-000148 · edgar.xml · nonDerivative · entry 2

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,055

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

SEC source: 0000874015-19-000148 · edgar.xml · nonDerivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.

SEC source: 0000874015-19-000146 · edgar.xml · derivative · entry 3

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant.

SEC source: 0000874015-19-000146 · edgar.xml · nonDerivative · entry 2

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,583

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019.

SEC source: 0000874015-19-000146 · edgar.xml · nonDerivative · entry 1

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019.

SEC source: 0000874015-19-000144 · edgar.xml · derivative · entry 4

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 1,000 shares

Expires 2024-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant.

SEC source: 0000874015-19-000144 · edgar.xml · nonDerivative · entry 2

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,683

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.795 to $64.92, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-19-000144 · edgar.xml · nonDerivative · entry 1

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019.